Premium
Bleomycin in xeroderma pigmentosum
Author(s) -
Short Joan,
Price Robert A.,
Pratt Charles B.
Publication year - 1973
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197302)31:2<449::aid-cncr2820310223>3.0.co;2-r
Subject(s) - xeroderma pigmentosum , bleomycin , medicine , pulmonary fibrosis , scalp , dermatology , pathology , fibrosis , chemotherapy , dna repair , biochemistry , chemistry , gene
A child with multiple squamous cell carcinomas associated with xeroderma pigmentosum (XP) was treated with Bleomycin on a twice weekly schedule utilizing a dosage of 30 mg/m 2 . Satisfactory clinical responses of facial and scalp lesions were observed. A total cumulative dose of 441 mg (630 mg/m 2 ) was administered before fatal pulmonary toxicity occurred after 18 weeks of therapy. Postmortem examination revealed a diffuse pulmonary disease consisting of atypical desquamative alveolitis and interstitial inflammatory changes with varying degrees of fibrosis.